- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Goal is to identify best candidates and optimal dosages for later studies at a major US facility
NanoViricides, Inc. (OTC BB: NNVC.OB), said that preliminary animal trials of the Company's HIV therapeutic candidates have begun at a BioSafety Level 3 (BSL-3) Laboratory facility in Boston, MA. The initial results are expected before the end of next month. These animal studies will be conducted by Dr. Krishna Menon, PhD, VMD, MRCS, a world-renowned authority in preclinical and toxicological studies of innovative therapeutics.
"The purpose of this initial study is twofold: To assess therapeutic efficacy and to determine the appropriate dosages of drug that should be used in the later animal study," said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding further, "if initial performance goals are met, it will be a critical first step in validating the Company's HivCide™-I as a potential treatment for HIV/AIDS. An expanded follow-on study will then be performed by researchers at a prestigious federal research institute."
NanoViricides, Inc. is currently developing injectable formulations for systemic viral diseases such as HIV, human flu, bird flu (H5N1), Ebola, rabies and Dengue as well as eye drops for the virulent eye disease, epidemic keratoconjunctivitis (EKC). "We believe that in the future, many of the nanoviricides, including HivCide-I, can potentially be delivered using long-acting skin-patch formulations," said Dr. Seymour, adding, "if successful, such skin patches will be a very useful treatment strategy in combatting chronic diseases like HIV and Hepatitis C. Not having to remember to take pills or injections on a strict schedule will be extremely important in assuring patient compliance and treatment success".
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016